secwatch.observer — SEC 8-K summary
======================================

Issuer:     LISATA THERAPEUTICS, INC. (LSTA)
CIK:        0000320017
Form:       8-K
Filed at:   2023-03-30T23:59:59+00:00
Accession:  0000320017-23-000010
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lisata Therapeutics reports FY2022 financial results and provides business update
--------------------------------------------------------------------------------

- Net loss for FY2022 was $54.2 million, including $30.4 million non-routine merger-related IPR&D expense.
- Cash, cash equivalents and marketable securities totaled $69.2 million as of December 31, 2022.
- LSTA1 Phase 2b ASCEND study in pancreatic cancer is ongoing; basket trial in other solid tumors planned for H1 2023.
- HONEDRA for critical limb ischemia is in pre-consultation with Japan's PMDA; partner search continues.
- XOWNA development suspended; LSTA201 proof-of-concept study did not show consistent kidney function improvement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/320017/000032001723000010/0000320017-23-000010-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/320017/000032001723000010/clbs-20230330.htm
  HTML page:      https://secwatch.observer/filing/0000320017-23-000010

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer